Drug factory · FDA FEI 3006118993
Eurofins Amatsi Analytics
Parc De Genibrat, Fontenilles, France
Problems found, fixed voluntarily at FDA's last inspection, May 20, 2026.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
5 drug inspections on record since 2014: 2 with no problems, 3 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Ferric Cation | Tests it | Shield TX (UK) Ltd | 73059-001 |
| Selexipag | Tests it | Actelion Pharmaceuticals US, Inc. | 66215-718 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| May 20, 2026 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Nov 3, 2023 | Problems found, fixed voluntarily | Bioresearch Monitoring | — |
| Aug 5, 2021 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Sep 28, 2016 | No problems found | Drug Quality Assurance | — |
| Feb 4, 2014 | No problems found | Drug Quality Assurance | — |
Registered with FDA for: analysis.